Sleep Disorders

Last updated 1 Jun 2026 · General Practice / Respiratory

📋 Key Information Summary

📋

Insomnia is the most prevalent sleep disorder in Australia, affecting approximately 20% of adults; cognitive behavioural therapy for insomnia (CBT-I) is first-line treatment, ahead of pharmacotherapy.
Obstructive sleep apnoea (OSA) affects an estimated 5–10% of Australian adults and is strongly associated with obesity, cardiovascular disease, and motor-vehicle accidents.
Central sleep apnoea (CSA) is less common and typically secondary to heart failure, opioid use, or high-altitude exposure; treat the underlying cause first.
Polysomnography (sleep study) remains the gold standard for diagnosing OSA, CSA, narcolepsy, and parasomnias; home sleep studies are suitable for uncomplicated suspected OSA.
Continuous positive airway pressure (CPAP) is first-line therapy for moderate-to-severe OSA; mandibular advancement splints are an alternative for mild-to-moderate disease or CPAP-intolerant patients.
Narcolepsy type 1 (with cataplexy) is caused by orexin/hypocretin deficiency; diagnosis requires a multiple sleep latency test (MSLT) showing mean sleep latency ≤8 minutes with ≥2 sleep-onset REM periods (SOREMPs).
Modafinil is first-line pharmacotherapy for narcolepsy-related excessive daytime sleepiness; sodium oxybate is used for cataplexy and disrupted nocturnal sleep.
Parasomnias include disorders of arousal (sleepwalking, night terrors) and REM sleep behaviour disorder (RBD); RBD in older adults is a strong prodromal marker for synucleinopathies (Parkinson disease, dementia with Lewy bodies).
Sleep hygiene education is a foundational component of management for all sleep disorders but alone is insufficient for chronic insomnia.
Excessive daytime sleepiness increases road-transport risk; clinicians must consider mandatory reporting obligations under state/territory legislation (e.g., Austroads fitness-to-drive guidelines).
Aboriginal and Torres Strait Islander Australians experience higher rates of sleep-disordered breathing and shorter sleep duration, driven by socioeconomic disadvantage and chronic disease burden.
Melatonin (prolonged-release) is PBS-listed for insomnia in adults ≥55 years; short-term benzodiazepines and Z-drugs should be limited to ≤4 weeks due to dependence risk.

Introduction & Australian Epidemiology

Sleep disorders encompass a broad range of conditions that impair the timing, quality, or quantity of sleep, leading to daytime dysfunction and reduced quality of life. The International Classification of Sleep Disorders, Third Edition (ICSD-3) categorises sleep disorders into insomnia disorders, sleep-related breathing disorders, central disorders of hypersomnolence, circadian rhythm sleep–wake disorders, parasomnias, and sleep-related movement disorders. This guideline focuses on the four most clinically significant presentations encountered in Australian general practice: insomnia, obstructive and central sleep apnoea, narcolepsy and idiopathic hypersomnia, and parasomnias.

In Australia, sleep disorders represent a major public-health burden. The 2022 Sleep Health Foundation national survey estimated that 33–45% of Australian adults report inadequate or poor-quality sleep on a regular basis. Chronic insomnia disorder affects approximately 15–20% of the adult population, with higher prevalence in women, older adults, and those with comorbid psychiatric illness. Obstructive sleep apnoea is diagnosed in 5–10% of adults, though the true prevalence may be higher when including undiagnosed disease; the increasing prevalence of obesity (affecting 31% of Australian adults in 2022, AIHW data) is a major driver. Narcolepsy is rare, with an estimated prevalence of 20–50 per 100,000, while REM sleep behaviour disorder occurs in approximately 1–2% of older adults.

The economic impact is substantial. The Sleep Health Foundation has estimated that sleep disorders cost the Australian economy over billion annually in healthcare expenditure, productivity losses, and accident-related costs. Untreated OSA alone contributes significantly to cardiovascular morbidity, motor-vehicle accidents, and workplace injuries.

⚠️

Fitness to drive: Excessive daytime sleepiness from any cause is a reportable safety concern. Clinicians should counsel patients regarding driving risk and be aware of mandatory notification obligations under state and territory road-transport legislation. Refer to the Austroads Assessing Fitness to Drive guidelines (2022 update) for specific requirements.

Insomnia & Basic Principles of Management

Chronic insomnia disorder, as defined by ICSD-3 and DSM-5, is characterised by difficulty initiating or maintaining sleep, early-morning awakening, or non-restorative sleep occurring at least three nights per week for at least three months, causing clinically significant distress or functional impairment. The condition is not attributable to another sleep disorder, medical condition, mental disorder, or substance use.

Classification

Type	Duration	Typical Cause	Management Approach
Acute / short-term	<3 months	Stressful life event, jet lag, acute illness	Reassurance, sleep hygiene, short-term hypnotic if needed
Chronic insomnia	≥3 months	Hyperarousal, conditioned arousal, comorbidities	CBT-I first-line; pharmacotherapy second-line
Comorbid insomnia	Variable	Psychiatric, pain, respiratory, medication-related	Treat comorbidity + CBT-I; avoid reflex hypnotic prescribing

Non-Pharmacological Management — CBT-I

Cognitive behavioural therapy for insomnia (CBT-I) is the recommended first-line treatment for chronic insomnia in adults of all ages, endorsed by the American Academy of Sleep Medicine (AASM), the European Sleep Research Society, and the Australasian Sleep Association (ASA). CBT-I is superior to pharmacotherapy in the long term and does not carry dependence or rebound-insomnia risks.

Core CBT-I components include:

Sleep restriction therapy: Limiting time in bed to actual sleep time, then gradually increasing as efficiency improves.
Stimulus control: Use the bed only for sleep and intimacy; leave the bedroom if unable to sleep within ~20 minutes.
Cognitive restructuring: Challenging maladaptive beliefs about sleep (e.g., catastrophising about sleep loss).
Sleep hygiene education: Consistent wake time, limiting caffeine and alcohol, minimising screen exposure before bed, optimising bedroom environment.
Relaxation training: Progressive muscle relaxation, mindfulness-based techniques.

💡

Accessing CBT-I in Australia: CBT-I can be delivered by clinical psychologists with sleep expertise. Digital CBT-I programmes (e.g., Sleepio™, Insomnia Coach) are increasingly available. Under Medicare, patients may access CBT-I via a Mental Health Treatment Plan (MBS item 80110–80125) providing up to 10 sessions per calendar year with a psychologist. Some state sleep services also offer group CBT-I programmes.

Pharmacological Management

Pharmacotherapy should be considered when CBT-I is insufficient, unavailable, or when insomnia is severe and causing acute functional impairment. Short-term use (≤4 weeks) is recommended for most hypnotic agents. Long-term use requires specialist review.

💊

Melatonin (prolonged-release)

Circadin® · Hypnotic (melatonin receptor agonist)

Adult dose 2 mg PO once daily, 1–2 hours before bedtime

Paediatric dose Not routinely recommended <18 years (off-label use under specialist guidance at 2–5 mg in some settings)

Renal adjustment No dose adjustment required

Hepatic adjustment Use with caution; reduced clearance in severe hepatic impairment

PBS status ✔ PBS General Benefit — adults ≥55 years with primary insomnia

💊

Temazepam

Temaze® · Normison® · Benzodiazepine hypnotic

Adult dose 10–20 mg PO at bedtime

Duration ≤2–4 weeks; avoid long-term use

Renal adjustment No significant adjustment; use lowest effective dose

Hepatic adjustment Reduce dose in hepatic impairment; prolonged half-life

PBS status ✔ PBS General Benefit

💊

Zolpidem

Stilnox® · Imovane® (zopiclone) · Z-drug hypnotic

Adult dose 5–10 mg PO at bedtime (5 mg in elderly)

Duration ≤2–4 weeks

Renal adjustment No significant adjustment

Hepatic adjustment Reduce dose; avoid in severe hepatic impairment

PBS status ✔ PBS General Benefit

💊

Suvorexant

Belsomra® · Orexin receptor antagonist

Adult dose 10–20 mg PO at bedtime (within 30 min of retiring); may increase to 20 mg if tolerated

Duration Can be used longer-term under specialist supervision

Renal adjustment No dose adjustment

Hepatic adjustment Max 10 mg in moderate hepatic impairment; avoid in severe

PBS status ⚠ PBS Authority Required — chronic insomnia refractory to CBT-I and ≥1 other hypnotic

🚨

Safety alert — Z-drugs and benzodiazepines: Avoid in the elderly where possible due to increased risk of falls, cognitive impairment, delirium, and hip fracture. The Beers Criteria (American Geriatrics Society) lists all benzodiazepines and Z-drugs as potentially inappropriate medications in older adults. If a hypnotic is essential in an elderly patient, melatonin (prolonged-release) is preferred. Zolpidem has been associated with complex sleep-related behaviours (sleep-driving, sleep-eating) — counsel patients accordingly.

Sleep Apnoea (Obstructive & Central)

Obstructive Sleep Apnoea (OSA)

OSA is characterised by repeated episodes of complete (apnoea) or partial (hypopnoea) upper-airway obstruction during sleep, resulting in oxyhaemoglobin desaturation, sleep fragmentation, and excessive daytime sleepiness. It is the most common form of sleep-disordered breathing.

Risk factors: Obesity (BMI ≥30), increased neck circumference (>43 cm males, >38 cm females), male sex, age >50 years, craniofacial abnormalities, tonsillar/adenoid hypertrophy (paediatric), family history, alcohol and sedative use, smoking, nasal obstruction, and supine sleeping position.

Severity Classification (AASM Criteria)

Mild

AHI 5–14 events/hour

Minimal daytime symptoms; snoring may be the only complaint. Mild oxyhaemoglobin desaturation (nadir SpO₂ 86–90%).

Setting: GP management; lifestyle modification; mandibular advancement splint consideration

Moderate

AHI 15–29 events/hour

Daytime somnolence, morning headaches, witnessed apnoeas. Moderate desaturation (nadir SpO₂ 80–85%).

Setting: Sleep physician review; CPAP or mandibular advancement splint; driving counselling

Severe

AHI ≥30 events/hour

Prominent daytime impairment, significant desaturation (nadir SpO₂ <80%), associated hypertension, arrhythmias.

Setting: Specialist management; CPAP first-line; assess cardiovascular comorbidity; mandatory driving counselling

Diagnosis

In-laboratory polysomnography (PSG): Gold standard; monitors EEG, EOG, EMG, airflow (nasal pressure + oronasal thermistor), respiratory effort (thoraco-abdominal belts), SpO₂, ECG, body position, and leg movements. Available at accredited sleep laboratories across Australian capital cities and major regional centres.
Home sleep apnoea testing (HSAT): Limited-channel devices (typically airflow, respiratory effort, SpO₂) suitable for adult patients with high pre-test probability of moderate-to-severe OSA and no significant comorbidities (e.g., heart failure, neuromuscular disease, suspected hypoventilation). The Australasian Sleep Association supports HSAT as a cost-effective pathway for uncomplicated OSA.
MBS item numbers: In-laboratory PSG — MBS item 12203 (sleep study); home-based studies may be billed under practice-based arrangements or state-funded sleep-service programmes.

Management of OSA

Lifestyle Modification

Weight loss (5–10% body weight reduces AHI by up to 50%), positional therapy (avoid supine sleep), alcohol avoidance, smoking cessation, and nasal obstruction management. These measures are foundational and should be recommended to all patients regardless of severity.

CPAP (Continuous Positive Airway Pressure)

First-line for moderate-to-severe OSA and for mild OSA with symptoms or cardiovascular risk. Auto-titrating CPAP (APAP) is commonly used. Average nightly use ≥4 hours is the adherence target. Supplied through sleep-lab or respiratory-medicine services with ongoing mask-fit support.

Mandibular Advancement Splint (MAS)

Fitted by a dentist with sleep-medicine training. Indicated for mild-to-moderate OSA, patients who decline or are intolerant of CPAP, or as combination therapy. Less effective than CPAP for severe disease but improves AHI and symptoms.

Surgical Options

Uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), hypoglossal nerve stimulation (Inspire®), or bariatric surgery for obesity-related OSA. Reserved for CPAP/MAS failure or specific anatomical obstruction. Refer to ENT or oral-maxillofacial surgery.

Central Sleep Apnoea (CSA)

CSA results from intermittent loss of ventilatory drive during sleep, without upper-airway obstruction. It is less common than OSA and usually secondary to:

Heart failure — Cheyne–Stokes respiration is the most common pattern of CSA in Australia, occurring in 25–50% of patients with heart failure with reduced ejection fraction (HFrEF).
Opioid and sedative use — suppresses central respiratory drive.
Brainstem/upper cervical cord pathology — stroke, tumour, Chiari malformation.
High-altitude exposure — transient CSA due to hypoxic ventilatory response instability.

⚠️

CSA in heart failure: The SERVE-HF trial demonstrated that ASV (adaptive servo-ventilation) increased mortality in patients with HFrEF (LVEF ≤45%) and predominantly central apnoeas. ASV is contraindicated in HFrEF with CSA. Optimisation of heart-failure therapy (ACEi/ARNI, beta-blockers, diuretics) is the primary approach. CPAP may be trialled cautiously in selected patients.

Treatment of CSA centres on managing the underlying condition. Supplemental oxygen, acetazolamide, and phrenic-nerve stimulation are emerging therapies used in specialist settings.

Narcolepsy & Idiopathic Hypersomnia

Narcolepsy

Narcolepsy is a chronic neurological disorder of central hypersomnolence caused by loss of orexin (hypocretin)-producing neurons in the lateral hypothalamus. Prevalence in Australia is estimated at 20–50 per 100,000, with onset typically in adolescence or early adulthood. Diagnosis is often delayed by 8–15 years.

Feature	Narcolepsy Type 1 (NT1)	Narcolepsy Type 2 (NT2)
Core symptom	Excessive daytime sleepiness (EDS)	EDS without cataplexy
Cataplexy	Present — sudden bilateral loss of muscle tone triggered by emotions (laughter most common)	Absent
CSF orexin-A	≤110 pg/mL (low/undetectable)	Normal (>200 pg/mL)
HLA association	HLA-DQB1*06:02 positive (>98%)	HLA-DQB1*06:02 positive (~50%)
MSLT criteria	Mean sleep latency ≤8 min + ≥2 SOREMPs (or 1 SOREMP + CSF orexin ≤110 pg/mL)	Mean sleep latency ≤8 min + ≥2 SOREMPs

Diagnosis

Epworth Sleepiness Scale (ESS): Screening tool; score ≥10 suggests pathological sleepiness. Validated in Australian populations.
Overnight PSG followed by MSLT: Must be performed the day after PSG (which should show ≥6 hours total sleep and exclude other causes). PSG excludes OSA and other sleep disorders; MSLT measures mean latency to sleep and SOREMPs across 4–5 nap opportunities at 2-hour intervals.
CSF orexin-A measurement: Lumbar puncture for CSF hypocretin-1 level — highly specific for NT1 when ≤110 pg/mL. Available at major Australian tertiary hospitals.
HLA typing: HLA-DQB1*06:02 — supportive but not diagnostic (present in ~20% of the general population).

Management of Narcolepsy

Treatment of Excessive Daytime Sleepiness

💊

Modafinil

Modavigil® · Wakefulness-promoting agent

Adult dose 200 mg PO in the morning, may increase to 400 mg daily (divided AM + midday)

Paediatric dose Not PBS-listed for children; off-label use from ~6 years under specialist guidance

Renal adjustment No adjustment; use caution in severe impairment

Hepatic adjustment Reduce dose by 50% in hepatic impairment

PBS status ⚠ PBS Authority Required — narcolepsy diagnosed by sleep specialist

💊

Armodafinil

Nuvigil® · R-enantiomer of modafinil

Adult dose 150–250 mg PO once daily in the morning

PBS status ⚠ PBS Authority Required — narcolepsy

💊

Dexamphetamine

Dexedrine® · Sympathomimetic amine

Adult dose 5–60 mg PO daily in divided doses (start 5 mg mane, titrate weekly)

PBS status ⚠ PBS Authority Required — narcolepsy, refractory to modafinil

💊

Pitolisant

Wakix® · Histamine H₃-receptor inverse agonist

Adult dose 4.5–36 mg PO once daily in the morning (titrate over 3 weeks)

Renal adjustment Max 18 mg/day if eGFR 30–60 mL/min; avoid if eGFR <30

PBS status ✘ Not PBS-listed — available via private prescription or Special Access Scheme

Treatment of Cataplexy

💊

Sodium oxybate

Xyrem® · CNS depressant (sodium salt of γ-hydroxybutyrate)

Adult dose 2.25–4.5 g PO nocte in two divided doses (first dose at bedtime, second 2.5–4 hours later); titrate over 8 weeks

Key indication Cataplexy + disrupted nocturnal sleep in NT1

Renal adjustment Sodium load — caution with fluid overload

PBS status ⚠ PBS Authority Required — narcolepsy with cataplexy, under specialist initiation

Idiopathic Hypersomnia

Idiopathic hypersomnia (IH) is characterised by excessive daytime sleepiness with prolonged, unrefreshing nocturnal sleep (≥10 hours) and severe sleep inertia (difficulty waking). Unlike narcolepsy, there is no cataplexy and MSLT shows mean sleep latency ≤8 minutes with <2 SOREMPs. CSF orexin-A is normal. The condition is less responsive to standard wake-promoting agents than narcolepsy. Treatment includes modafinil, dexamphetamine, or low-dose clarithromycin (off-label, modulates GABA-A receptors) under specialist supervision. Flumazenil (IV or sublingual) has shown benefit in some refractory cases but is not widely available.

Parasomnias (Sleepwalking, Night Terrors, REM Sleep Behaviour Disorder)

Parasomnias are undesirable physical events or experiences that occur during sleep entry, within sleep, or during arousal from sleep. They are classified by the sleep stage in which they arise.

Non-REM Parasomnias (Disorders of Arousal)

Feature	Sleepwalking (Somnambulism)	Night Terrors (Sleep Terrors)
Sleep stage	N3 (slow-wave sleep) — first third of night	N3 (slow-wave sleep) — first third of night
Age group	Peak prevalence 4–8 years; ~4% of adults	Peak 4–12 years; ~2% of adults
Presentation	Ambulation during sleep; eyes open but blank expression; limited responsiveness; amnesia for the event	Sudden arousal with intense fear, screaming, autonomic activation (tachycardia, diaphoresis); inconsolable; amnesia for the event
Precipitants	Sleep deprivation, fever, stress, alcohol, sedatives, noise, full bladder	Same as sleepwalking; also overtiredness in children
Management	Safety measures first; reassurance; treat triggers; scheduled awakenings (paediatrics); low-dose clonazepam if frequent/injurious	Parental reassurance; safety; avoid precipitants; scheduled awakenings; rarely requires pharmacotherapy

💡

Safety first — non-REM parasomnias: Injury prevention is paramount. Secure windows and doors, remove sharp objects from the bedroom, install stair gates (paediatrics), consider ground-floor sleeping, and lock access to kitchens and garages. In adults with injurious parasomnias, low-dose clonazepam 0.5–2 mg at bedtime may be trialled (off-label). Avoid alcohol and sleep deprivation, which are potent triggers.

REM Sleep Behaviour Disorder (RBD)

RBD is characterised by loss of normal REM-sleep atonia, resulting in dream-enacting behaviours that may be violent and cause injury to the patient or bed partner. Unlike non-REM parasomnias, patients typically recall dream content and the episodes occur in the latter half of the night (when REM sleep predominates).

Critical clinical significance: RBD is now recognised as a prodromal marker of alpha-synucleinopathies. Longitudinal studies demonstrate that 80–90% of patients with idiopathic RBD will eventually develop Parkinson disease, dementia with Lewy bodies, or multiple system atrophy, with a median interval of 10–15 years from RBD onset. All patients with newly diagnosed RBD should be referred to a neurologist for baseline assessment and longitudinal monitoring.

Diagnosis of RBD

Polysomnography: Demonstrates REM sleep without atonia (RWA) on EMG — increased phasic or tonic chin/limb EMG activity during REM. This is the diagnostic hallmark.
Clinical history: Dream-enacting behaviours (talking, shouting, punching, kicking) reported by bed partner. Most patients are males aged >50 years.
Exclude mimics: Obstructive sleep apnoea (can cause REM-related arousals mimicking RBD), non-REM parasomnias, nocturnal seizures, PTSD-related nightmares.

Management of RBD

💊

Melatonin (immediate-release or prolonged-release)

Circadin® / compounded · First-line for RBD

Dose for RBD 3–12 mg PO at bedtime (start 3 mg, titrate); higher doses than used for insomnia

Advantage Fewer side effects than clonazepam; preferred first-line per AASM practice guidelines

PBS status ⚠ PBS Authority Required — Circadin for adults ≥55 years; higher doses may require compounding (non-PBS)

💊

Clonazepam

Rivotril® · Benzodiazepine — second-line for RBD

Dose for RBD 0.5–2 mg PO at bedtime

Cautions Daytime sedation, cognitive impairment, falls in elderly, respiratory depression — avoid in patients with OSA or dementia

PBS status ✔ PBS General Benefit

⚠️

RBD and neurodegenerative disease: All patients diagnosed with RBD should have neurological assessment including baseline cognitive screening (MoCA), motor examination (MDS-UPDRS), and autonomic-function testing. Longitudinal follow-up is essential. Avoid antipsychotics and metoclopramide in RBD patients, as they may worsen extrapyramidal features or mask emerging Parkinsonism.

Investigations — Overview

Essential Overnight Polysomnography (PSG) Gold standard for OSA, CSA, narcolepsy, RBD, parasomnias. MBS item 12203. Available at accredited public and private sleep laboratories nationally. Requires GP referral to sleep physician or respiratory physician.

Available Home Sleep Apnoea Testing (HSAT) Limited-channel device for high-probability OSA in adults without significant comorbidities. Increasingly available through respiratory physicians and some GP-accessible programmes. More cost-effective than in-lab PSG for straightforward cases.

Essential Multiple Sleep Latency Test (MSLT) Performed the day after overnight PSG. Five nap opportunities at 2-hour intervals measuring sleep latency and SOREMPs. Diagnostic for narcolepsy (mean latency ≤8 min + ≥2 SOREMPs). Requires specialist referral.

Specialist CSF Orexin-A (Hypocretin-1) Level Lumbar puncture. Level ≤110 pg/mL is diagnostic for narcolepsy type 1. Available at major tertiary hospitals (e.g., Royal Melbourne, Royal Prince Alfred, Flinders). Requires specialist request.

Available Maintenance of Wakefulness Test (MWT) Assesses ability to stay awake — used to evaluate treatment efficacy in narcolepsy and for fitness-to-drive assessments. Four 40-minute sessions in quiet, dim environment.

Available Actigraphy Wrist-worn accelerometer recording rest–activity patterns over 1–2 weeks. Useful for circadian rhythm disorders and quantifying sleep–wake patterns in insomnia. Does not replace PSG for respiratory or parasomnia diagnosis.

Available Epworth Sleepiness Scale (ESS) Validated 8-item self-report questionnaire assessing daytime sleepiness propensity. Score ≥10 suggests pathological sleepiness. Useful for screening and monitoring treatment response. No cost; can be administered in general practice.

Referral HLA Typing (HLA-DQB1*06:02) Supportive test for narcolepsy. Sensitivity >98% for NT1 but low specificity (~20% of general population carry the allele). Available through hospital immunology/haematology laboratories.

Special Populations

🤰

Pregnancy

OSA in pregnancy: Prevalence increases, especially in the third trimester and with pre-eclampsia/gestational diabetes. Untreated OSA associated with adverse maternal (hypertensive disorders, gestational diabetes) and fetal outcomes (preterm birth, growth restriction). CPAP is safe and first-line.

Hypnotics: Avoid benzodiazepines and Z-drugs (Category D). Melatonin — limited safety data; not recommended routinely. Sleep hygiene and CBT-I strategies are preferred.

Modafinil: Contraindicated in pregnancy (Category D — teratogenicity signal from European registry data). Effective contraception required during use.

Refer complex sleep disorders in pregnancy to a sleep physician with obstetric medicine liaison.

👶

Paediatrics

OSA in children: Most common cause is adenotonsillar hypertrophy. First-line treatment is adenotonsillectomy. Prevalence peaks at 2–6 years. Obesity is an increasing contributor in adolescents. Refer to paediatric ENT/sleep medicine.

Insomnia: Behavioural interventions are first-line (consistent bedtime routine, positive sleep associations). Melatonin is used off-label under paediatric specialist guidance for neurodevelopmental conditions (ASD, ADHD).

Narcolepsy: Childhood onset possible. Modafinil and sodium oxybate may be used under specialist supervision. Psychosocial support and school accommodations are essential.

Parasomnias: Sleepwalking and night terrors are common and usually self-limiting. Reassure parents; emphasise safety. Refer if persistent, injurious, or atypical.

👴

Elderly (≥65 years)

Insomnia: Very common; often multifactorial (pain, nocturia, polypharmacy, mood disorders). CBT-I adapted for older adults is effective. Prolonged-release melatonin (Circadin® 2 mg) is PBS-listed for ≥55 years. Avoid benzodiazepines and Z-drugs (Beers Criteria).

OSA: Highly prevalent; however, clinical significance of mild OSA in the very elderly is debated. CPAP remains beneficial for symptomatic moderate-to-severe disease. Assess adherence and quality of life.

RBD: Predominantly affects males >50 years. First-line melatonin 3–12 mg. Clonazepam second-line but use cautiously due to falls and cognitive risks. Neurological follow-up mandatory (synucleinopathy risk).

Always review medications contributing to sleep disruption (SSRIs can trigger RBD, diuretics cause nocturia, corticosteroids cause insomnia).

🫘

Renal Impairment

Sleep disorders in CKD: Insomnia, restless legs syndrome, OSA, and excessive daytime sleepiness are all more prevalent in CKD/dialysis patients. Sleep quality worsens with declining eGFR.

Dosing considerations: Melatonin — no adjustment needed. Temazepam — use lowest dose; active metabolites may accumulate. Zolpidem — reduce dose. Modafinil — caution; limited data. Sodium oxybate — sodium load problematic in fluid-overloaded renal patients.

Polysomnography interpretation may be complicated by fluid shifts and volume overload in dialysis patients — in-lab PSG preferred over HSAT.

🫁

Hepatic Impairment

Relevance: Hepatic encephalopathy disrupts sleep architecture (inverted sleep–wake cycle). Cirrhosis associated with increased prevalence of OSA, restless legs, and insomnia.

Dosing considerations: Benzodiazepines — avoid in hepatic encephalopathy (risk of precipitating/worsening). Zolpidem — reduce dose, avoid in severe impairment. Modafinil — reduce dose by 50%. Melatonin — reduced clearance; monitor. Suvorexant — max 10 mg in moderate impairment, avoid in severe.

Hepatology referral for sleep disturbance in cirrhosis if first-line measures fail.

🛡️

Immunocompromised

Relevance: Immunosuppressed patients (transplant recipients, HIV, chemotherapy) may have atypical or severe parasomnias. Medication-related insomnia is common (corticosteroids, tacrolimus, interferons).

OSA: Post-transplant weight gain and immunosuppressant-related myopathy may worsen OSA. Screening for OSA post-transplantation is advisable.

Minimise hypnotic use; prioritise non-pharmacological strategies. Drug interactions with immunosuppressants should be reviewed by a pharmacist or transplant physician.

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Health Considerations

Prevalence and Burden

Aboriginal and Torres Strait Islander Australians experience disproportionately higher rates of sleep-disordered breathing, short sleep duration (<6 hours/night), and excessive daytime sleepiness compared with non-Indigenous Australians. Data from the Busselton Health Study and the Australian Institute of Health and Welfare (AIHW) indicate that sleep problems contribute significantly to the health gap between Indigenous and non-Indigenous Australians, with downstream effects on cardiovascular disease, diabetes, and injury rates.

Overweight and Obesity

Obesity prevalence in Aboriginal and Torres Strait Islander adults is higher than the national average (estimated 38–42% vs 31%), driving increased OSA burden. Culturally appropriate weight-management programmes, including those delivered through Aboriginal Community Controlled Health Organisations (ACCHOs), are critical to reducing OSA severity.

Access to Sleep Services

Geographic remoteness is a major barrier. Accredited sleep-laboratory services are concentrated in metropolitan and large regional centres. For remote and very remote communities, home sleep apnoea testing (HSAT) is a valuable diagnostic pathway, supported by telehealth consultation with sleep specialists. The Royal Flying Doctor Service and state-based outreach programmes facilitate access in some regions.

CPAP Adherence and Support

CPAP adherence in Indigenous communities may be limited by housing conditions (overcrowding, lack of reliable power), cultural factors, health literacy, and limited access to equipment maintenance and mask-fitting support. Culturally safe CPAP education delivered by Aboriginal Health Workers and Practitioners (AHWPs) improves uptake and adherence. Equipment supply through state/territory respiratory programmes (e.g., Queensland Sleep Health Outreach Programme) is essential.

Insomnia and Social Determinants

Insomnia in Aboriginal and Torres Strait Islander communities is often intertwined with psychosocial stressors including grief, intergenerational trauma, overcrowded housing, noise, and mental health conditions (depression, anxiety, PTSD, substance use). Culturally informed, trauma-aware approaches to insomnia management are essential. CBT-I should be adapted for cultural context and delivered by trained AHWPs or clinical psychologists with experience in Indigenous health. Digital CBT-I may have limited utility where internet access is unreliable.

Paediatric OSA

Aboriginal and Torres Strait Islander children have higher rates of otitis media, upper-respiratory infections, and adenotonsillar hypertrophy, contributing to elevated paediatric OSA prevalence. Adenotonsillectomy rates are higher, but access to paediatric sleep studies and specialist review varies significantly by region. Early identification and management in primary care through ACCHOs is a priority.

Mandatory Reporting and Transport

In remote communities, loss of driving privileges due to untreated sleepiness or OSA-related impairment has severe consequences for access to healthcare, employment, and cultural activities. Clinicians should balance mandatory reporting obligations with proactive management pathways (e.g., expedited CPAP initiation) to minimise time off-road. Liaison with licensing authorities (state/territory transport departments) and the patient is essential.

📚 References

1. American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed, text revision. Darien, IL: AASM; 2023.
2. Sweetman A, Lack L, Catcheside PG, et al. Developing a successful and sustainable model for the management of insomnia disorder in Australian primary care: the Torrens University insomnia treatment and research programme. Nature and Science of Sleep. 2023;15:569–580.
3. Australasian Sleep Association. Position paper: the diagnosis and management of adult obstructive sleep apnoea in Australian primary care. Respirology. 2022;27(5):355–371.
4. Sleep Health Foundation. Awake Australia: The Economic Cost of Inadequate Sleep. Adelaide: Sleep Health Foundation; 2022.
5. Randerath W, Verbraecken J, Andreas S, et al. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep. Eur Respir J. 2017;49(1):1600959.
6. Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive servo-ventilation for central sleep apnoea in systolic heart failure (SERVE-HF): a randomised controlled trial. Lancet. 2015;386(10010):2221–2231.
7. Dauvilliers Y, Arnulf I, Lecendreux M, et al. Pitolisant for the treatment of narcolepsy: results of the Harmony 1 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(9):735–746.
8. Arnulf I, Zeitzer JM, File J, et al. Kleine–Levin syndrome: a systematic review of 186 cases in the literature. Brain. 2005;128(12):2763–2776. [Note: IH reference] Trotti LM. Idiopathic hypersomnia. Sleep Med Clin. 2017;12(3):331–344.
9. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019;142(3):744–759.
10. Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol. 2015;72(6):707–712.
11. Austroads. Assessing Fitness to Drive. 4th ed. Sydney: Austroads; 2022 (updated).
12. Australian Institute of Health and Welfare (AIHW). Sleep problems as a risk factor for chronic conditions. Cat. no. PHE 320. Canberra: AIHW; 2023.
13. Reutrakul S, Mokhlesi B. Obstructive sleep apnea and diabetes: a state of the art review. Chest. 2017;152(5):1070–1086.
14. Gringras P, Nir T, Breddy J, et al. Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2017;56(11):948–957.
15. Aboriginal and Torres Strait Islander Health Performance Framework. Sleep health and wellbeing. Canberra: Australian Government Department of Health; 2023. [HPF data tables]

for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.

Preventive health

Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction

Paracetamol ± NSAID; manual therapy

2–6 weeks

Provocable on palpation; no red flags

Thoracic compression fracture

Paracetamol; ± calcitonin; DXA + osteoporosis Rx

6–12 weeks healing

Elderly; osteoporosis; acute onset

ACS (posterior MI)

Aspirin 300 mg, GTN, heparin; urgent PCI

Time-critical

ECG, troponin; CV risk factors

Aortic dissection

IV labetalol; urgent CT aortogram; surgery (Type A)

Time-critical

Tearing pain; BP differential >20 mmHg

Vertebral osteomyelitis

IV antibiotics (vancomycin + ceftriaxone initially); ID consult

6 weeks IV antibiotics

Fever, elevated CRP, IV drug use

Biliary colic / cholecystitis

Paracetamol ± morphine; lap cholecystectomy

Surgical within 72 h (cholecystitis)

RUQ/infrascapular; post-prandial; RUQ US

📚 References

1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.

for PBS-listed medicines at participating pharmacies.

Cultural safety

Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.

Medication adherence

Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.

Specific conditions

Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.

Referral pathways

Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).

for PBS-listed medicines at participating pharmacies.

Cultural safety

Medication adherence

Specific conditions

Referral pathways

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).